Xencor Inc., a biotechnology firm specializing in the development of antibody and protein therapeutics for cancer and autoimmune inflammation, has seen recent regulatory activity regarding its ownership structure. According to a Schedule 13G amendment filed on November 16, 2026, the Biotechnology Value Fund and its related entities have disclosed a collective stake in the company’s common stock.
The filing indicates that the Biotechnology Value Fund and its general partners maintain a holding of approximately four to five percent of Xencor’s outstanding shares. Additionally, other associated investment vehicles hold a minority interest of less than one percent. The beneficial ownership of these shares is distributed among the fund’s general partners, its investment manager, and a specific individual who serves as both a director and an officer of the fund.
The documentation explicitly clarifies that these acquisitions were made without the intent to exert control over Xencor Inc. The holdings are maintained in strict compliance with applicable securities regulations. The amendment, which was formally signed by the fund’s authorized representative to affirm the accuracy of the data, underscores the passive nature of this investment.
Xencor Inc., which has been publicly traded on the Nasdaq since its initial public offering on December 3, 2013, continues to operate within the healthcare sector. As of the market close on November 16, 2026, the company’s stock was priced at 34.5 USD, with a market capitalization of 2.65 billion USD. While the company has experienced significant volatility over the past year—ranging from a 52-week low of 10.375 USD to a high of 40.6 USD—this latest regulatory filing provides clarity regarding the institutional interest held by the Biotechnology Value Fund.




